Sangamo Therapeutics, Inc. (SGMO) Stock: Seeing Gains In Today’s Session


Sangamo Therapeutics, Inc. (SGMO) is working its way for to the top in the market in today’s trading session. The company, one that is focused on the biotech industry, is currently trading at $9.85 after heading up 5.46% so far today. In terms of biotechnology companies, there are a number of aspects that have the ability to cause movement in the market. News is one of the most common reasons for movement. Here are the most recent headlines associated with SGMO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-08-19 08:30AM Sangamo Therapeutics Announces New Scientific Advisory Board
Nov-07-19 04:57AM Edited Transcript of SGMO earnings conference call or presentation 6-Nov-19 10:00pm GMT
Nov-06-19 05:15PM Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates
04:01PM Sangamo Therapeutics Reports Third Quarter 2019 Financial Results
09:00AM Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting

However, any time investors are making an investing decision, investors should focus on far more than news, this is especially the case in the speculative biotechnology sector. Here’s what’s happening with Sangamo Therapeutics, Inc..

Recent Trends From SGMO

While a single session gain, like the gain that we’re seeing from Sangamo Therapeutics, Inc. may make some investors jump for joy, a single session move by itself should not be the reason for a decision to, or not to, invest in a company. It is always important to dig into trends for a period longer than a single session. When it comes to SGMO, below are the trends that investors have seen:

  • Past 5 Sessions – In the last 7 days, SGMO has seen a change in price in the amount of 4.23%.
  • Past 30 Days – The monthly ROI from Sangamo Therapeutics, Inc. works out to 22.36%.
  • Quarterly – In the last three months, the stock has produced a ROI that comes to -12.29%
  • Bi-Annually – Throughout the last six months, we’ve seen a performance that works out to 0.61% from the stock.
  • Year To Date – Since the the last trading session of last year SGMO has resulted in a ROI of -14.20%.
  • Annually – Finally, over the last year, we have seen movement in the amount of -31.12% from SGMO. Over this period, the stock has sold at a high price of -32.21% and a low price of 57.35%.

Crucial Ratios

Looking at a few ratios associated with a stock generally gives investors a look of how risky and/or rewarding a stock pick may be. Here are some of the important ratios to look at when digging into SGMO.

Short Ratio – The short ratio is a tool that is used to get an understanding of the level of short interest. As the short ratio goes higher, it shows that more investors believe that the value of the stock is headed for declines. Across the sector, biotech stocks can have a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the industry. Nonetheless, with regard to Sangamo Therapeutics, Inc., the stock’s short ratio comes to 14.00.

Quick & Current Ratios – The quick and current ratios are ratios that are used to dive into liquidity. Essentially, they measure the company’s abilities to pay its debts as they mature using quick assets or current assets. In the biotechnology industry, companies rely heavily on continued investor support, the current and quick ratios can look bad. However, some good picks in the biotech sector do have strong current and quick ratios. When it comes to SGMO, the quick and current ratios come to 5.60 and 5.60 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets owned by the company. In this particular case, that ratio comes in at 3.89.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the price of shares. Many clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotech space, this is an important ratio to consider. As it relates to SGMO, the cash to share value is 3.98.

How Analysts Feel About Sangamo Therapeutics, Inc.

While it’s never a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to use their analysis to validate your own when it comes to making investment decisions in the biotech space. Below are the most recent moves that we’ve seen from analysts as it relates to SGMO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-26-19 Initiated H.C. Wainwright Buy $16
Nov-14-18 Downgrade JP Morgan Overweight → Neutral
Nov-09-18 Downgrade Guggenheim Buy → Neutral
Oct-10-18 Initiated Guggenheim Buy
Jun-20-18 Initiated BofA/Merrill Buy $24

Is Big Money Interested In Sangamo Therapeutics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in SGMO, here’s what we’re seeing:

  • Institutions – As it stands now, institutional investors own 71.00% of the company. Nonetheless, it is worth considering that institutional ownership has moved in the amount of 0.81% over the last 3 months.
  • Insiders – with regard to insiders, members of the management team and others close to SGMO currently own 0.10% of Sangamo Therapeutics, Inc.. Their ownership of the company has changed by -4.32% throughout the past quarter.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 110.78M shares of Sangamo Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, SGMO has a float of 110.78M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to SGMO, the short percent of the float is 15.03%.

What We’ve Seen In Financial Results

What have ween seen from SGMO in terms of financial results?Here is the data:

  • Analyst Expectations – Currently, Wall St. analysts are expecting that SGMO will come up with earnings per diluted share that totals up to be -1.34, with -0.34 to be announced in the earnings report for the current quarter. Although this is not associated with earnings, since we’re chatting on the topic of Wall St. analysts, Sangamo Therapeutics, Inc. is presently graded as a 2.10 when rated on a scale from 1 to 5 on which 1 is the poorest possible Wall St. analyst grade and 5 is the best possible rating.
  • 5-Year Sales – In the past half decade, Sangamo Therapeutics, Inc. has reported a change in revenue that works out to be 28.50%. Earnings per diluted share over the last 5 years have seen movement in the amount of -8.20%.
  • Q/Q – In terms of quarter over quarter earnings performance, or Q/Q data as it is commonly referred to as in the world of humans, Sangamo Therapeutics, Inc. has created a change in earnings in the amount of -54.80%. SGMO has also experienced a change when it comes to sales that adds up to -18.20%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, by my very nature, I have the ability to learn by myself. Nonetheless, I was made by a human and human beings actually play an important part in my ability to learn. Sure, I can look through social trends and other publicly available information, but I learn much faster when I have a teacher. If you would to teach me something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at something? If so, leave a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here